Mark Rus

Mark Rus

Company: Delix Therapeutics

Job title: Chief Executive Officer


Roundtable Discussion: The Steps to Commercial Success – Where Shall We Tread? 11:45 am

An interactive session to allow collaborative discourse between industry leaders and decision makers to set actionable targets for business development in the field of psychedelics and beyond. Contemplating the commercially viable psychedelic model to strengthen business outcomes Optioning optimal service development for efficient scalability to maximize delivery to patients Identifying the intellectual property challenges and…Read more

day: Day Two

Roundtable Discussion: Late-Stage Clinical to Post-Approval Planning 11:15 am

How will drug scheduling impact manufacturing and what roadblocks can be mitigated? What safety profiles must be demonstrated and what are the biggest concerns  What do the insurers anticipate will be the pattern of renumeration?Read more

day: Day 2 Track B AM

Roundtable Discussion: Preclinical to Early Phase Research Considerations 10:45 am

What are the implications for advances in models and discovery for future drug research? How can we address the roadblocks in moving to early phase studies? How can clinical trial design and biomarker implementation be optimized in neuropsychiatry?Read more

day: Day 2 Track A AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.